This roundtable series looks at combination treatments in the unresectable or metastatic bladder cancer population, as discussed by key opinion leaders at virtual live events and interviews.

Patients With Advanced Bladder Cancer Given Combination Therapies

CheckMate 274 Confirms Benefit of Nivolumab for Bladder Cancer

April 15, 2025

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in patients with high PD-L1.

Exploring Neoadjuvant and Adjuvant Therapies for Patients With MIBC

April 11, 2025

During a live event, Matthew Galsky, MD discussed neoadjuvant and adjuvant options for a patient case including nivolumab or dose-dense MVAC.

Updated Efficacy Shows Nivolumab Boosts Survival in High-Risk MIBC

March 19, 2025

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant nivolumab in patients with bladder cancer.

Participants Discuss ctDNA and NGS in Muscle-Invasive Bladder Cancer

February 26, 2025

During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder cancer.

Reviewing the Options for Bladder Cancer in Different Settings

January 09, 2025

Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.

IO Trials Change Practice in Localized and Metastatic Bladder Cancer

December 18, 2024

Petros Grivas, MD, PhD, discusses the key trials of bladder cancer using immunotherapy he highlighted during a Case-Based Roundtable event.

Trials Needed for Sequencing Checkpoint Inhibitors in Bladder Cancer

November 22, 2024

Petros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.

Differing Trial Designs for Immunotherapy in MIBC Yield Favorable Outcomes

October 30, 2024

Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.

Opinions on Treatment Split for Prominent Questions in Bladder Cancer

October 22, 2024

Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a Case-Based Roundtable event.

Surprising Findings With Nivolumab in Bladder Cancer Trials

September 18, 2024

Matthew Galsky, MD, discusses why some physicians were surprised at the positive outcomes of nivolumab trials in bladder cancer compared with trials of similar agents.

Nivolumab Shows Improved DFS in ITT and PD-L1–High Bladder Cancer

August 13, 2024

Matthew Galsky, MD, discusses the disease-free survival of nivolumab vs placebo in patients with high-risk muscle-invasive bladder cancer.